Order byBest matchMost fresh

Novavax scores narrower Covid vaccine approval

Digest more
Top News
Overview
Impacts
Healthy Returns: Novavax scores narrower Covid vaccine approval after delay
Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's Covid-19 vaccine after more than a month of delay b

Continue reading

After delay, FDA approves Novavax’s Covid-19 vaccine, but only for older people and those at high risk
The FDA is making it more difficult for Americans to get vaccinated for covid
US FDA advisers to consider if new COVID shots should target LP.8.1 subvariant
The U.S. Senate plans to vote this week to bar California's landmark plan to end the sale of gasoline-only vehicles by 2035 that has been adopted by 11 other states, Majority Leader John Thune said on...

Continue reading

Annual COVID-19 Shots For Healthy Younger Adults, Children Will No Longer Be Routinely Approved
US regulators say annual COVID-19 shots for healthy younger adults and children will no longer be routinely approved
FDA sets new COVID booster guidelines for healthy adults under 65
Vaccine makers have argued that because COVID vaccines have been changed annually to match the circulating strain of the virus, new placebo-controlled trials could delay availability of the shots unt...

Continue reading

F.D.A. Poised to Restrict Access to Covid Vaccines
FDA to limit future Covid-19 shots to older people and those at risk of serious infection
Who can get updated COVID vaccines this fall? FDA will OK for high-risk groups, calls for new clinical trials
"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at low risk," the agency said in an article published by The New England Journal of Medicine, authored by FDA Commissioner Dr. Martin Makary and his new top vaccines official, Dr. Vinay Prasad.
Feedback